Oncolytics Biotech is conducting clinical trials in multiple indications with the objective of developing REOLYSIN® as a human cancer therapeutic. The current clinical program comprises human trials using REOLYSIN® both alone and in combination with chemotherapy, delivered via local and/or intravenous administration. In May 2010, the Company commenced enrollment for its first Phase III clinical trial, REO 018, investigating the intravenous administration of REOLYSIN® in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers.
REOLYSIN® is currently available exclusively in a clinical trial setting. It has not been approved in any jurisdiction and is not available for purchase. Oncolytics and its clinical partners are conducting clinical trials in a number of countries worldwide, including Canada, the United States and the United Kingdom.
The Company and its employees have no influence upon the inclusion of a patient in a clinical trial. If the patient’s physician determines that he or she may be a suitable trial candidate, they can contact a participating center. Contact information, as well as inclusion and exclusion criteria, for US and international participating centers, can be found at www.clinicaltrials.gov for studies with a US component.